TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 173nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 315nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 26nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 17nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 75nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 267nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 9nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 30nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 4nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 62nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 5nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 11nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 14nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 25nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 64nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 76nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 52nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 23nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 526nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 68nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 394nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataIC50: 329nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 16nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 9.70nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 120nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 7.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 580nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 2.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 27nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 1.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 3.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 670nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 330nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 50nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 95nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 28nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 50nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty
US Patent
Cancer Therapeutics Crc Pty
US Patent
Affinity DataKd: 1.90E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair